Abstract：
BACKGROUND:We studied the extent of BRCA1/2 genetic testing to help select the surgical approach for patients with breast cancer in Japan remains unclear. PATIENTS AND METHODS:The study subjects were female patients with primary unilateral invasive breast cancer considered as candidates for breast-conserving surgery who underwent preoperative BRCA1/2 genetic testing. A retrospective analysis was performed on the results of BRCA1/2 genetic testing and surgical method selection using national registration data from the Japanese Hereditary Breast and Ovarian Cancer Syndrome Consortium. RESULTS:Our study included 318 female patients. Among these patients, 23.7% of patients with BRCA1/2 mutations and 61.8% of patients without these variants underwent breast-conserving surgery (P < .01). Among the patients with BRCA1/2 mutations, those who chose breast-conserving surgery tended not to undergo risk-reducing salpingo-oophorectomy (P < .05). Among the patients with BRCA1/2 mutations who underwent mastectomy for the affected side, 31.8% received contralateral risk-reducing mastectomy. Patients diagnosed with breast cancer under the age of 50 years were more likely to have contralateral risk-reducing mastectomy than patients over the age 50 years (P < .05). CONCLUSIONS:Patients with BRCA1/2 mutations tend to choose mastectomy. However, it is speculated that the final surgical method selection is made in consideration of not only the test results but also with careful consideration of the patient, taking into account other factors including individual values for risk-reducing surgeries and the age of breast cancer onset.
journal_name
Clin Breast Cancerjournal_title
Clinical breast cancerauthors
Inuzuka M,Watanabe C,Yokoyama S,Kuwayama T,Akashi-Tanaka S,Arai M,Nakamura S,Registration Committee of the Japanese HBOC consortium.doi
10.1016/j.clbc.2020.08.004subject
Has Abstractpub_date
2020-08-20 00:00:00eissn
1526-8209issn
1938-0666pii
S1526-8209(20)30209-3pub_type
杂志文章abstract：BACKGROUND:Postmenopausal women with osteoporosis had a 66% relative risk reduction for invasive breast cancer over 8 years of raloxifene therapy in the randomized, placebo-controlled 4-year MORE (Multiple Outcomes of Raloxifene Evaluation) trial and the CORE (Continuing Outcomes Relevant to Evista) trial, a 4-year fol...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究,随机对照试验
doi：10.3816/CBC.2009.n.008
更新日期：2009-02-01 00:00:00
abstract：BACKGROUND:Medical isotopes are required for sentinel node lymphoscintigraphy in breast cancer, but are in critical shortage. Our center uses a modification of the standard SC, called CRC, that has been shown to require less medical isotope for the same procedure. Our objective was to determine if there was a significa...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.07.006
更新日期：2015-02-01 00:00:00
abstract：:Intravenous bisphosphonates are the preferred treatment to prevent skeletal complications for patients with breast cancer and bone metastases. Pamidronate, a single-nitrogen bisphosphonate, was the early standard of care for such patients based on 2 large, placebo-controlled trials involving 754 patients. Zoledronic a...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2005.n.014
更新日期：2005-06-01 00:00:00
abstract：:Over the past 30 years, much progress has been made in adjuvant chemotherapy for patients with early-stage breast cancer. The introduction of anthracyclines and, recently, taxanes has significantly improved the efficacy of adjuvant chemotherapy and has provided useful insight regarding future development of even more ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2004.s.006
更新日期：2004-01-01 00:00:00
abstract：:The perinatal period, childhood, and adolescence are important intervals for breast cancer risk development. Endogenous estrogen exposure is thought to be highest in utero, and exposure to estrogens throughout life plays an important role in increasing breast cancer risk. Some evidence suggests that breast tissue is n...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/CBC.2008.n.038
更新日期：2008-08-01 00:00:00
abstract：:[18F]fluorodeoxyglucose positron emission tomography (FDG-PET) is a metabolic imaging modality that has increasing applications in oncology, neurology, and cardiology. Among the oncology applications, breast cancer is one of the most extensively studied diseases. FDG-PET has been performed for diagnosis, staging, and ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2003.s.016
更新日期：2003-04-01 00:00:00
abstract：PURPOSE:To evaluate, in a series of early breast cancer (BC) patients treated with hypofractionated adjuvant radiotherapy (RT), whether N-terminal-pro hormone B-type natriuretic peptide (NT-proBNP) and high-sensitivity cardiac troponin I assay measurements can predict acute clinical or preclinical cardiotoxicity. PATI...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.09.005
更新日期：2020-09-10 00:00:00
abstract：BACKGROUND:Although magnetic resonance imaging (MRI) is a useful imaging modality for invasive cancer, its role in preoperative surgical planning for ductal carcinoma in situ (DCIS) has not been established. We sought to determine whether preoperative MRI affects surgical treatment and outcomes in women with pure DCIS....
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2011.n.006
更新日期：2011-03-01 00:00:00
abstract：:The histopathologic subtypes of breast cancer, including invasive ductal carcinoma (IDC) and invasive lobular carcinoma (ILC), differ in terms of risk factors, progression, and response to treatment. The PubMed/Medline, Web of Science, and Scopus databases were searched up to February 2020 for published studies on the...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2020.03.007
更新日期：2020-08-01 00:00:00
abstract：BACKGROUND:We investigated the effect of basal protein expression on trastuzamab response in patients with HER2-positive (HER2(+)) breast cancer who received trastuzamab (T) and in HER2(+) breast cancer cell lines. PATIENTS AND METHODS:Expression of cytokeratin (CK) 5/6, CK14, and epidermal growth factor receptor (EGF...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.06.001
更新日期：2015-12-01 00:00:00
abstract：PURPOSE:The objective of this study was to evaluate whether p27kip1 downregulation is a prognostic factor in patients with inflammatory breast carcinoma (IBC). PATIENTS AND METHODS:Fifty-eight patients with IBC were treated between January 1994 and July 2002. Median age was 49 years. Thirty-eight patients had baseline...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2006.n.045
更新日期：2006-10-01 00:00:00
abstract：:Traditionally in the treatment of primary breast cancer, axillary lymph node dissection (ALND) plays an important role. However, a substantial and increasing percentage of patients appear to have no nodal involvement and have been subjected to ALND unnecessarily. The first reason to perform an ALND is axillary nodal s...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2002.n.034
更新日期：2002-12-01 00:00:00
abstract：:Breast cancer stem cells (BCSCs), characterized by the CD44(+)/CD24(-/low) marker, are attributed with features that are demonstrated by the disease itself, such as growth of tumor, recurrence, metastases, and multiple drug resistance. This review concerns the emergence and expediency of BCSCs in treating relapse and ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2012.09.017
更新日期：2013-02-01 00:00:00
abstract：BACKGROUND:Brain metastasis (BM) is a life-threatening event in breast cancer patients. Identifying patients at a high risk for BM can help to adopt screening programs and test preventive interventions. We tried to identify the incidence of BM in different stages and subtypes of breast cancer. PATIENTS AND METHODS:We ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2017.08.004
更新日期：2018-04-01 00:00:00
abstract：BACKGROUND:Disrupting the autophagic balance to trigger autophagic death may open new strategies for cancer therapy. Transcription factor EB (TFEB) is a master regulator of lysosomal biogenesis and may play a role in cancer biology and clinical behavior. METHODS:The expression of TFEB and the lysosomal cancer cell con...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.11.006
更新日期：2017-06-01 00:00:00
abstract：BACKGROUND:Eribulin has efficacy in patients with progression after ≥ 1 chemotherapeutic regimen for metastatic breast cancer (MBC). A short disease-free interval (DFI) and previous use of taxanes in the neoadjuvant or adjuvant setting have been associated with worse outcomes for patients receiving first-line chemother...
journal_title：Clinical breast cancer
pub_type： 杂志文章,多中心研究
doi：10.1016/j.clbc.2018.12.012
更新日期：2019-04-01 00:00:00
abstract：INTRODUCTION:This study evaluated the association between aromatase inhibitor (AI) therapy and cognitive function (over a 6-month period) in a cohort of patients aged ≥ 60 years compared with an age-matched healthy control group, and it evaluated changes in regional cerebral metabolism as measured by positron emission ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2013.10.010
更新日期：2014-04-01 00:00:00
abstract：:This article discusses the rationale for 2 methods of making estimates of the benefit of letrozole as extended adjuvant hormonal therapy after 5 years of tamoxifen. It uses information from the Overview metaanalyses to develop general rules for making estimates of remaining risk of relapse for women completing 5 years...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/cbc.2004.n.047
更新日期：2004-10-01 00:00:00
abstract：:Over the past 30 years there has been an increased use of neoadjuvant (or primary) chemotherapy for treating patients with breast cancer. However, while it is clear that chemotherapy given in the adjuvant setting after surgery does prolong patients' overall and disease-free survival, the evidence that chemotherapy in ...
journal_title：Clinical breast cancer
pub_type： 临床试验,杂志文章,随机对照试验
doi：10.3816/cbc.2002.s.015
更新日期：2002-10-01 00:00:00
abstract：BACKGROUND:Letrozole withdrawal for 3 months might permit estrogenic stimulation in residual resistant breast cancer disease susceptible to letrozole reintroduction. We investigated the impact of a 3-month letrozole-free interval on serum estradiol levels in patients with early stage breast cancer. PATIENTS AND METHOD...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2015.03.007
更新日期：2015-10-01 00:00:00
abstract：BACKGROUND:The American Joint Committee on Cancer (AJCC) staging system is the reference standard for describing the extent of neoplastic disease on the basis of the size of primary tumor (T), and the presence of regional lymph node (N) involvement and distant metastasis (M). Multiple foci of invasive breast carcinoma ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2020.11.018
更新日期：2020-12-05 00:00:00
abstract：:Breast-conserving therapy (BCT) consists of segmental mastectomy followed by postoperative radiation therapy (RT) to the whole breast. At least 6 prospective randomized trials have proven the equivalence of BCT to mastectomy. However, BCT remains underused and, most importantly, a sizable proportion of patients with i...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2003.n.030
更新日期：2003-10-01 00:00:00
abstract：:Breast cancer patients who present with nodal metastasis receive neoadjuvant chemotherapy (NAC) with increasing frequency and can have complete pathologic response after treatment. In this clinical scenario, sentinel node mapping and biopsy are gaining acceptance instead of axillary dissection to avoid morbidity. Biop...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.1016/j.clbc.2018.01.004
更新日期：2018-08-01 00:00:00
abstract：INTRODUCTION:For patients who have an ipsilateral breast cancer recurrence following prior breast-conserving surgery and radiation, total mastectomy generally is recommended. However, little is known about the suitability and outcomes of nipple-sparing mastectomy (NSM) with immediate breast reconstruction for the treat...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2016.10.011
更新日期：2017-07-01 00:00:00
abstract：:Currently, the interest in cognitive functioning following chemotherapy is rapidly expanding as is reflected in a growing number of published studies on this topic. Although most studies are indicative of cognitive deficits after chemotherapy, definite conclusions on the role of chemotherapy on cognitive function can ...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2002.s.020
更新日期：2002-12-01 00:00:00
abstract：BACKGROUND:Luminal-type breast cancers are the most abundant subtype. Endocrine therapies targeting estrogen receptor (ER) or estradiol (E2) synthesis have achieved marked improvement in disease-free and overall survival of ER-positive cancers. However, approximately one-third of these cancers are poorly responsive to ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2014.11.002
更新日期：2015-04-01 00:00:00
abstract：:Overexpression of the p185/HER2 protein is seen in 20%-25% of primary breast cancers and is associated with poor prognosis. Recent phase II and III clinical trials demonstrate that trastuzumab is active against breast tumors, both as a single agent and in combination with chemotherapy. In patients with HER2-overexpres...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2001.s.003
更新日期：2001-10-01 00:00:00
abstract：BACKGROUND:Causes of racial disparities in breast cancer survival remain unclear. This study assesses overall survival (OS) after diagnosis between black and white women and examines factors that might correlate with this disparity. PATIENTS AND METHODS:Data were obtained from the Medical College of Georgia Tumor Regi...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.3816/CBC.2010.n.008
更新日期：2010-02-01 00:00:00
abstract：:During the past decade, improvements in treatment-planning tools, computer and imaging technologies, and new therapeutic modalities have allowed radiation to be delivered in a conformal fashion while minimizing treatment toxicity. It is important that physicians involved in breast cancer treatment recognize the numero...
journal_title：Clinical breast cancer
pub_type： 杂志文章,评审
doi：10.3816/cbc.2004.n.002
更新日期：2004-02-01 00:00:00
abstract：BACKGROUND:The purpose of this study was to assess the activity and safety of the combination of vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-negative (HER(-)) metastatic breast cancer (MBC). PATIENTS AND METHODS:Patients (42) enrolled in trial A received intravenous (i.v.) VNR 25 mg/m2 on ...
journal_title：Clinical breast cancer
pub_type： 杂志文章
doi：10.1016/j.clbc.2011.11.001
更新日期：2012-02-01 00:00:00
